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Cardioembolic stroke accounts for 20–30% of acute brain infarctions in Japan. This condition is often
severe and has poor outcomes. Non-valvular atrial ﬁbrillation (NVAF) is the most common cardiac
source of emboli in cardioembolic stroke. Anticoagulants are recommended for preventing stroke in
patients with NVAF, and these patients were usually treated with warfarin. However, the use of
warfarin has many limitations. Approximately half of the patients with NVAF, who show indications for
warfarin treatment, are treated with warfarin. Bleeding complications, including intracranial hemor-
rhages, are common during warfarin treatment; this is a huge concern of warfarin treatment. Warfarin-
associated intracranial hemorrhage is often severe and devastating. Several novel anticoagulants that
can overcome the limitations of warfarin have been introduced in the market or are under develop-
ment. In this review, we discuss the pharmacological properties of novel anticoagulants and current
strategies of anticoagulation therapy for preventing stroke in patients with NVAF.
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Several new anticoagulants have been developed recently to
overcome the limitations of warfarin. The new anticoagulants are
either thrombin inhibitors, such as dabigatran, or factor Xa inhibitors,
such as rivaroxaban, apixaban, and edoxaban, and these anticoagu-
lants suppress either thrombin or factor Xa directly [1]. The char-
acteristics of new anticoagulants differ from those of warfarin and are
summarized in Table 1. In particular, their absorption time is short,
the time-to-peak-concentration (Tmax) is 1–4 h, and the serum
concentration corresponds to the anticoagulatory effect. Although
the half-life of the new anticoagulants is about 12 h, the rivaroxabanrt Rhythm Society. Published by E
: þ81 92 846 8485.and the edoxaban are taken once a day and the dabigatran and the
apoxaban twice a day. The efﬁcacy of the new anticoagulants is not
inﬂuenced by food intake or vitamin K levels; therefore, food
restriction is not required during treatment. Compared to warfarin,
the new anticoagulants interact much less with other medicines. The
therapeutic range of the new anticoagulants is wide, and the effect of
anticoagulation can be predicted from the amount of drug adminis-
tered; thus, it is not necessary to monitor their anticoagulation effect.
Overall, the characteristics of these novel anticoagulants are such that
treatment with these anticoagulants does not have many of the
difﬁculties that are frequently encountered with warfarin treatment.
2. Results of phase III trials of the novel anticoagulants
The efﬁcacy and safety of dabigatran, a direct thrombin inhibitor,
and rivaroxaban and apixaban, direct factor Xa inhibitors, have beenlsevier B.V. All rights reserved.
Table 1
Characteristics of warfarin and novel anticoagulants.
Warfarin New anticoagulants
Monitoring Required Not required
Established Not established
Inﬂuence of food Vitamin K-rich food None
Interactions with other medicines Frequent Small
Absorption Fast, but its anticoagulatory effect appears several days later Fast (Tmax of 1–4 h)
Half-life 40 h 12 h
Risk of stroke with missed doses Low High
Perioperative management Complicated Uncomplicated
Resistance Reported Not reported
Volume of research Large Small
Price Inexpensive Expensive
1 mg 9.6 yen Dabigatran
150 mg bid, 530.4 yen
110 mg bid, 465.4 yen
Rivaroxaban
15 mg qd, 530.4 yen
10 mg qd, 372.4 yen
Methods of reversal
Vitamin K Effective Not effective
Gastric lavage or oral administration of activated charcoal Not effective Effective, soon after taking dabigatran
Hemodialysis Not effective Possiblea
FFP Effective Possiblea
PCC Effective Possiblea
rFVII Effective Possiblea
FFP, fresh frozen plasma; PCC, prothrombin complex concentrate; rFVII, recombinant activated factor VII.
a No available clinical data.
Table 2
Results of phase III trials to compare the efﬁcacy of novel anticoagulants and warfarin.
Dabigatran (1) Rivaroxaban (2) Apixaban (3)
150 mg 110 mg 20 mg qd 5 mg qd
Stroke and systemic embolism Superior Non-inferior Non-inferior Superior
Major bleeding Non-inferior Superior Non-inferior Superior
Ischemic stroke Superior
Any death Superior
Major and clinically relevant bleeding Superior Superior Superior
Gastrointestinal bleeding Inferior Inferior
Hemorrhagic stroke Superior Superior Superior Superior
Intracranial hemorrhage Superior Superior Superior Superior
Withdrawal Inferior Inferior Superior
Analysis was on-treatment for rivaroxaban (2), and intention-to-treat for dabigatran (1) and apixaban (3). Superior, non-inferior, and inferior indicate that superiority, non-
inferiority and inferiority to warfarin were proven, respectively in each phase III trial.
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Fig. 1. Rate of stroke and systemic embolism expressed per subject years in patients treated with a new anticoagulant (dabigatran (2), rivaroxaban, (3) or apixaban (4);
gray bars) and in patients treated with warfarin (black bars) as determined in each study. Drug dosage and method of analysis (intention-to-treat or on treatment) are
indicated on the x-axis.
M. Yasaka / Journal of Arrhythmia 28 (2012) 324–329 325compared to those of warfarin in phase III trials [2–4]. The patients
and warfarin management, particularly the time in therapeutic range,
differed between these studies, precluding direct comparison of
the primary or secondary endpoints and adverse events. However, adescriptive summary of the ﬁndings of each trial is presented in
Table 2. All 3 drugs were not inferior to warfarin in terms of incidence
of stroke, systemic embolism as the primary endpoint, and major
bleeding (Fig. 1) [2–4]. Superiority to warfarin was observed
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Fig. 2. Rate of intracranial bleeding expressed per subject–years in patients treated with a new anticoagulant (dabigatran (2), rivaroxaban, (3) or apixaban (4); gray bars)
and in patients treated with warfarin (black bars) as determined in each study. Drug dosage and method of analysis (intention-to-treat or on treatment) are indicated on
the x-axis.
Fig. 3. A schematic representation obtained from the Japanese Circulation Society illustrating anticoagulation use in patients non-valvular arterial ﬁbrillation, taken
from (5).
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tran (150mg dose) and apixaban. Moreover, dabigatran (110mg
dose) and apixaban were shown to be superior to warfarin in
preventing major bleeding. The incidence of hemorrhagic stroke
and intracranial hemorrhage in patients treated with the novel
anticoagulants was signiﬁcantly lower than that in patients treated
with warfarin (Fig. 2). The incidence of ischemic stroke was lower in
patients treated with dabigatran (150mg) than in patients treated
with warfarin. Gastrointestinal bleeding was frequently seen in
patients treated with dabigatran (150mg) and rivaroxaban. Com-
pared to patients treated with warfarin, patients treated with
dabigatran showed withdrawal more frequently and those treated
with apixaban showed withdrawal less frequently.3. Use of different anticoagulants according to risk
stratiﬁcation
The CHADS2 score is used to estimate the risk of stroke in
patients with NVAF and to help determine whether anticoagulanttherapy is required. This score is based on a point system in which
2 points are assigned for a history of stroke or transient ischemic
attack (TIA) and 1 point each is assigned for congestive heart
failure, history of hypertension, an age of at least 75 years, and
diabetes. When the CHADS2 score is 2 or more, the annual risk of
stroke is 4% or more. Therefore, a CHADS2 score of 2 or more is
considered a high risk for stroke and is an indication for warfarin
treatment. When the CHADS2 score is 1, warfarin treatment is not
immediately recommended, but the beneﬁts of reducing stroke
incidence are considered against the risk of major bleeding. A
previous study showed that compared to warfarin, dabigatran is
associated with lower rates of stroke, systemic embolism, major
bleeding, and intracranial bleeding in patients with low (0–1),
medium (2), and high (Z3) CHADS2 scores [5]. Given the small
number of patients with a CHADS2 score of 0 in that study (only
2.5% of the patients were in the low-risk group), the Japanese
Circulation Society released an urgent statement recommending
dabigatran for patients with CHADS2 scores of 1 [6] (Fig. 3).
Although the CHADS2 score is useful for evaluating the risk of
stroke in NVAF patients, about half of all NVAF patients have a score
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be administered or not, to these patients because the risk of annual
incidence of stroke is so low for such patients that the beneﬁts of
anticoagulation therapy do not clearly exceed the increased risk of
major bleeding. The CHA2DS2-VASc score has been proposed as a
complement for the CHADS2 score, since it uses additional risk factors
to predict stroke risk in NVAF patients [8]. The scoring system of the
CHA2DS2-VASc score ranges from 0 to 9; 1 point each is assigned for
congestive heart failure, hypertension, an age of 65–74 years, diabetes
mellitus, vascular disease, and female gender, and 2 points are
assigned for an age of at least 75 years and a previous incidence of
stroke or TIA.
A nationwide cohort study conducted in Denmark demonstrated
that at 1-year follow-up, the rate of thromboembolism per 100
people per year was 1.67 (95% conﬁdence interval, 1.47–1.89) in
patients with a CHADS2 score of 0 and 0.78 (0.58–1.04) in patients
with a CHA2DS2-VASc score of 0 [7]. This rate was found to rise to
4.75 (4.45–5.07) and 2.01 (1.70–2.36) in patients with a CHADS2 and
CHA2DS2-VASc scores of 1, respectively, and to 7.34 (6.88–7.82) and
3.71 (3.36–4.09) in patients with a CHADS2 and CHA2DS2-VASc
scores of 2, respectively. Patients were categorized as low- (score
of 0), intermediate- (score of 1), or high-risk (score of 2 or more), and
the C statistics at the 10-year follow-up was 0.812 (0.796–0.827)
when patients were categorized according to the CHADS2 score
and 0.888 (0.875–0.900) when categorized according to the
CHA2DS2-VASc score. Thus, the CHA2DS2-VASc score performed
better than the CHADS2 score in predicting thromboembolism.
Furthermore, these results indicate that patients categorized as low-
risk by CHA2DS2-VASc are truly at a low risk for thromboembolism
and that anticoagulation should be recommended for NVAF patients
with a CHA2DS2-VASc score of 2 or more and considered for NVAF
patients with a CHA2DS2-VASc score of 1.
Although the CHA2DS2-VASc score was found to be superior to
the CHADS2 score in predicting patients at risk for thromboembo-
lism, it is more complicated than CHADS2. Therefore, we typically
perform CHADS2 scoring for all NVAF patients, and recommend
dabigatran, rivaroxaban, or warfarin treatment for patients with
a score of 2 or more and dabigatran treatment for patients with a
score of 1. For patients who have a CHADS2 score of 0 or have
a CHADS2 score of 1 but develop renal dysfunction or other adverse
effects after dabigatran treatment, CHA2DS2-VASc scoring is per-
formed for more precise stratiﬁcation. Dabigatran, rivaroxaban, or
warfarin are recommended for patients with a CHA2DS2-VASc
score of 2 or more and considered for patients with a CHA2DS2-VASc
score of 1. Patients with a CHA2DS2-VASc score of 0 have a low risk
for thromboembolism and may not beneﬁt from anticoagulants;
however, dabigatran or rivaroxaban may be considered as these
anticoagulants have a low risk of inducing intracranial bleeding.
This strategy is depicted in Fig. 4.CHADS2 ≥ 2
dabigatran / rivaroxaban / warfarin
1 dabigatran
CHA2DS2-VASc
0
≥2
1
0 not administered or
recommended
recommended
recommendeddabigatran / rivaroxaban / warfarin
dabigatran / rivaroxaban / warfarin
considered
considered
dabigatran / rivaroxaban
Fig. 4. A schematic representation showing the strategy of anticoagulant use
according to CHADS2 and CHA2DS2-VASc scores.4. Prevention of intracranial and major bleeding
History of stroke or TIA is as a major risk factor for intracranial
hemorrhage and recurrent stroke [9–11]. Therefore, it is neces-
sary to pay attention to preventing intracranial bleeding and
recurrent stroke in NVAF patients with a history of stroke or TIA.
Compared to warfarin, the aforementioned novel anticoagulants
show the same efﬁciency in suppressing stroke and systemic
embolism and are associated with a much lesser incidence of
intracranial bleeding [1–4]; therefore, the novel anticoagulants
should be the ﬁrst choice for preventing stroke recurrence in
NAVF patients with a history of stroke or TIA. To avoid brain
hemorrhage, it is essential to manage risk factors such as blood
pressure, blood glucose, smoking, and excess alcohol consump-
tion. Of these, management of blood pressure is the most
important, and the lower the blood pressure the better for
reducing the risk of brain hemorrhage or brain infarction [12].
High blood pressure is associated with intracranial bleeding, and
the optimal cut-off value for preventing intracranial bleeding is
130/81 mmHg, as determined by receiver–operating characteris-
tic curve analysis [13]. In patients treated with antithrombotic
agents, blood pressure can be controlled to values below 130/
80 mmHg in a manner similar to the one used for patients with
kidney disease, past history of myocardial infarction, and diabetes
mellitus [14].
The clinical spectrum of intracranial hemorrhage is similar for
patients treated with warfarin and dabigatran [10]. Absolute rates
of intracranial hemorrhage across all sites and of both fatal and
traumatic intracranial hemorrhages are lower with dabigatran
than with warfarin [10]. Concomitant aspirin use is the most
important modiﬁable independent risk factor for intracranial
hemorrhage. In a recent report, patients with atrial ﬁbrillation
who were at risk for stroke and were aged less than 75 years
showed a lower incidence of intracranial and extracranial bleed-
ing when treated with dabigatran than when treated with
warfarin [15]. In patients aged 75 years or more, compared to
warfarin treatment, dabigatran treatment was associated with
lower risk of intracranial bleeding risk but similar or higher risk of
extracranial bleeding [15]. Bleeding risk increased with age and
degree of renal dysfunction, was inversely related to body weight,
and increased with concomitant administration of antiplatelet
therapy [15]. Caution is, therefore, required when administering
anticoagulants to a patient who is aged 75 years or older or
has low body weight or renal dysfunction or if the patient is
concomitantly administered antiplatelets.
A new bleeding risk index, called HAS-BLED, which is scored from
0 to 9 for several factors, namely, hypertension, abnormal renal/liver
function, stroke, bleeding history or predisposition, labile interna-
tional normalized ratio, elderly age (465 years), and concomitant
drug/alcohol use, has been proposed for NVAF patients [16]. This
simple score provides a practical tool to assess the individual bleeding
risk of an NVAF patient and can potentially support decision-making
regarding antithrombotic therapy. The incidence of major bleeding
was reported as 3.74%/year or more in patients with a HAS-BLED
score of 3 or more, indicating that attention should be given to major
bleeding in these patients [16].5. Intracranial bleeding
Compared to warfarin, dabigatran, rivaroxaban, and apixaban
have a much lower risk of inducing intracranial hemorrhage [2–4].
Intracranial bleeding during anticoagulation is often devastating, and
the lower risk associated with these novel anticoagulants is, therefore,
beneﬁcial for patients requiring anticoagulation. The lower risk of
intracranial bleeding with the novel anticoagulants may be explained
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reaction in the coagulation cascade (Fig. 5). The concentration of
tissue factor in the brain is same as that in the lungs and placenta and
higher than that in other parts of the body [17]. However, warfarin
suppresses vitamin K-dependent carboxylation of coagulation factor
VII, resulting in low concentrations of VIIa and low production of
tissue factor and VIIa complex. Thus, it is difﬁcult for the coagulation
cascade to start and for bleeding to stop.6. Intermittent anticoagulation
The plasma concentrations of the novel anticoagulants vary
over the course of a day, with 1 or 2 peaks and troughs in their
concentration vs. time curves [1–4]. In the peak phases, coagula-
tion is suppressed by direct inhibition of thrombin or factor Xa.
However, in the trough phases, it seems that the coagulation
cascade is not fully inhibited. One potential explanation for the
lack of thrombus formation during the trough phase is the
presence of physiological coagulation inhibitors, such as antith-
rombin, protein C, and protein S, tissue factor pathway inhibitor,
and the ﬁbrinolytic system, which would suppress thrombus
formation if they are active during the trough phase (Figs. 5 and 6).
Continuous activation of thrombin may reduce the activity of
physiological coagulation inhibitors and the ﬁbrinolytic system
by exhausting factors related to coagulation. Intermittent antic-
oagulation induced by the novel anticoagulants, as well as
continuous anticoagulation induced by warfarin, is thought to
suppress the continuous activation of thrombin, thus preventing
thrombus formation in the cardiovascular system.7. Monitoring coagulation levels
Coagulation levels can be monitored after warfarin treatment
by measuring the prothrombin time (PT). However, monitoring is
not needed for novel anticoagulants because these drugs have a
much wider therapeutic range than warfarin. Nonetheless, in
patients at high risk of major bleeding, the physician may decide
to evaluate the coagulation levels. Protocols for measurement of
coagulation levels in patients treated with novel anticoagulants
that have peak and trough phases in their concentration curves
have not been established yet. The concentrations of dabigatran
and rivaroxaban are related to activated partial thrombin time
(APTT) and PT, respectively [18,19], and major bleeding during
treatment with these anticoagulants may be checked by measur-
ing APTT or PT, respectively. Prolonged APTT (more than 80 s) in
the trough phase is related to major bleeding during treatment
with dabigatran [20,21]. The relationship between major bleeding
and PT during rivaroxaban treatment has not yet been studied.
Ischemic events may be assessed by measuring the plasma levels
of molecular markers of the coagulation system, such as pro-
thrombin fragment 1þ2, thrombin–antithrombin complex, and
soluble ﬁbrin monomer complex (Fig. 7). Further investigation
is needed to determine the optimum method for assessing
major bleeding and ischemic events during treatment with novel
anticoagulants.8. Management of major bleeding
Hemorrhagic complications are the most common adverse
events associated with both anticoagulants and antiplatelet
agents. Patients should be aware of these risks, and physicians
should have knowledge on how to manage bleeding complica-
tions. It is important to treat the bleeding as promptly and
efﬁciently as possible. For patients with major bleeding during
treatment with novel anticoagulants, oral medication should be
ceased, bleeding should be stopped by mechanical compression
or by surgical interventions, and circulating blood volume and
blood pressure should be maintained by appropriate intravenous
drip infusion [18]. As much as 80% of dabigatran is excreted from
the kidney; therefore, intravenous infusion and induction of
diuresis can be beneﬁcial when managing major bleeding during
dabigatran treatment. For patients with intracranial hemorrhage,
treatment to suppress blood pressure should be provided. The
Tmax of dabigatran, when taken with food, is 4 h. Therefore, it
may be important to perform gastric lavage or oral administration
of activated charcoal if bleeding occurs within 4 h of dabigatran
M. Yasaka / Journal of Arrhythmia 28 (2012) 324–329 329administration. The circulatory system may be supported by
supplementation of endogenous procoagulant factors, such as
fresh frozen plasma, and factor IX complex (prothrombin complex
concentrate [PCC]) containing factors II, VII, IX, and X, or recom-
binant factor VII. Preclinical studies have reported that PCC and
recombinant factor VII inhibit prolongation of bleeding time after
administration of dabigatran in rats [22,23]. In a clinical study on
healthy volunteers, PCC did not reverse the anticoagulant effects
of dabigatran as assessed by measuring APTT, but it did reverse
the anticoagulation effects of rivaroxaban [19]. Further studies
are needed to verify the effects of PCC, recombinant factor VII, and
fresh frozen plasma on bleeding during treatment with new
anticoagulants. Hemodialysis to remove dabigatran may be use-
ful. Finally, the development of antibodies that can neutralize
dabigatran may offer an important option for patients with severe
bleeding [24].Conﬂict of interest
None.
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